IL7 and breast carcinoma: To investigate whether IL-7–CBD + CBD–IL-12 dual therapy can synergize with αPD-1 immunotherapy, we designed an experiment in which mice received intravenous cytokines of either of the single agents, or the dual therapy, or the triple combination with αPD-1 in the orthotopic 4T1 highly immunosuppressive breast cancer model (Fig. 4A and fig.